30 March 2023 
EMA/CHMP/137148/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Breyanzi 
lisocabtagene maraleucel  
On 30 March 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Breyanzi. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb Pharma 
EEIG. 
The CHMP adopted a new indication. For information, the full indication for Breyanzi will be as follows2: 
Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell 
lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large 
B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed 
within 12 months from completion of, or are refractory to, first-line 
chemoimmunotherapy. 
Breyanzi is indicated for the treatment of adult patients with relapsed or refractory DLBCL, 
PMBCL and FL3B, after two or more lines of systemic therapy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
